Eloxx Pharmaceuticals (NASDAQ:ELOX) Earns Outperform Rating from Analysts at Lifesci Capital

Lifesci Capital initiated coverage on shares of Eloxx Pharmaceuticals (NASDAQ:ELOX) in a research report released on Wednesday morning,Benzinga reports. The brokerage issued an outperform rating and a $40.00 price objective on the stock.

Separately, Guggenheim assumed coverage on Eloxx Pharmaceuticals in a report on Monday, July 20th. They issued a “buy” rating and a $43.00 price target on the stock. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Eloxx Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $41.50.

Eloxx Pharmaceuticals Trading Down 0.5%

ELOX opened at $11.94 on Wednesday. The stock’s 50-day simple moving average is $17.18. Eloxx Pharmaceuticals has a fifty-two week low of $11.30 and a fifty-two week high of $17.50. The firm has a market capitalization of $8.24 million, a price-to-earnings ratio of -0.78 and a beta of -1,891.27.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.